Role of adjuvant therapy in intermediate-risk cervical cancer patients - Subanalyses of the SCCAN study.
Adjuvant treatment
Cervical cancer
GOG criteria
Intermediate risk
Radial surgery
Radiotherapy
Journal
Gynecologic oncology
ISSN: 1095-6859
Titre abrégé: Gynecol Oncol
Pays: United States
ID NLM: 0365304
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
received:
13
12
2022
revised:
12
01
2023
accepted:
13
01
2023
pmc-release:
01
03
2024
pubmed:
28
1
2023
medline:
15
3
2023
entrez:
27
1
2023
Statut:
ppublish
Résumé
The "intermediate-risk" (IR) group of early-stage cervical cancer patients is characterized by negative pelvic lymph nodes and a combination of tumor-related prognostic risk factors such as tumor size ≥2 cm, lymphovascular space invasion (LVSI), and deep stromal invasion. However, the role of adjuvant treatment in these patients remains controversial. We investigated whether adjuvant (chemo)radiation is associated with a survival benefit after radical surgery in patients with IR cervical cancer. We analyzed data from patients with IR cervical cancer (tumor size 2-4 cm plus LVSI OR tumor size >4 cm; N0; no parametrial invasion; clear surgical margins) who underwent primary curative-intent surgery between 2007 and 2016 and were retrospectively registered in the international multicenter Surveillance in Cervical CANcer (SCCAN) study. Of 692 analyzed patients, 274 (39.6%) received no adjuvant treatment (AT-) and 418 (60.4%) received radiotherapy or chemoradiotherapy (AT+). The 5-year disease-free survival (83.2% and 80.3%; P Among patients with IR early-stage cervical cancer, radical surgery alone achieved equal disease-free and overall survival rates to those achieved by combining radical surgery with adjuvant (chemo)radiotherapy.
Identifiants
pubmed: 36706646
pii: S0090-8258(23)00014-8
doi: 10.1016/j.ygyno.2023.01.014
pmc: PMC10281542
mid: NIHMS1906746
pii:
doi:
Types de publication
Multicenter Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
195-202Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declared no conflicts of interest.
Références
Clin Transl Oncol. 2020 Feb;22(2):270-278
pubmed: 31981078
Int J Gynaecol Obstet. 2020 Jun;149(3):298-302
pubmed: 32246761
Int J Gynecol Cancer. 2019 May 27;:
pubmed: 31133601
Int J Gynecol Cancer. 2021 Jun;31(6):829-834
pubmed: 33962994
Gynecol Oncol. 1999 May;73(2):177-83
pubmed: 10329031
Gynecol Oncol. 2018 Dec;151(3):438-443
pubmed: 30348519
Radiother Oncol. 2018 Jun;127(3):404-416
pubmed: 29728273
Int J Gynaecol Obstet. 2019 Apr;145(1):129-135
pubmed: 30656645
Ann Surg Oncol. 2017 Oct;24(11):3406-3412
pubmed: 28785898
Int J Gynecol Cancer. 2022 Oct 3;32(10):1219-1226
pubmed: 36511890
Arch Geschwulstforsch. 1982 May;52(3):223-9
pubmed: 6751268
Int J Gynecol Cancer. 2018 Jul;28(6):1226-1231
pubmed: 29958236
Int J Gynecol Cancer. 2022 Sep 13;:
pubmed: 36100282
Eur J Cancer. 2021 Oct 16;158:111-122
pubmed: 34666213
Int J Gynecol Cancer. 2021 Jan;31(1):52-58
pubmed: 33303568
Int J Gynecol Cancer. 2022 Sep 13;:
pubmed: 36100280
Int J Gynecol Cancer. 2006 May-Jun;16(3):1112-8
pubmed: 16803494
Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):169-76
pubmed: 16427212
Cochrane Database Syst Rev. 2012 May 16;(5):CD007583
pubmed: 22592722
Oncology. 2020;98(12):853-858
pubmed: 32683361